Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

PT-141 Palatin.

Petter Hedlund1

  • 1Department of Clinical Pharmacology, University of Lund, F-blocket, Universitetssjukhuset, 22185 Lund, Sweden. petter.hedlund@klinfarm.lu.se

Current Opinion in Investigational Drugs (London, England : 2000)
|May 12, 2004
PubMed
Summary

Palatin is developing PT-141, a peptide nasal spray, for erectile dysfunction (ED) and female sexual dysfunction. Phase IIb trials for ED were completed, with Phase III trials planned for early 2005.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The significance of endocannabinoid receptors and endocannabinoids in the lower urinary and genital tract.

World journal of urology·2025
Same author

Drugs to affect the smooth musculature of the human ureter - an update with integrated information from basic science to the use in medical expulsion therapy (MET).

World journal of urology·2024
Same author

The Rho-kinase inhibitor Y27632 promotes ureteral relaxation in an in vivo rat model for partial ureteral obstruction.

World journal of urology·2023
Same author

Expression and distribution of the transient receptor potential cationic channel ankyrin 1 (TRPA1) in the human seminal vesicles.

Health science reports·2022
Same author

Long-term consequences of bilateral cavernous crush injury in normal and diabetic rats: a functional study.

International journal of impotence research·2021
Same author

The transient receptor potential A1 ion channel (TRPA1) modifies in vivo autonomous ureter peristalsis in rats.

Neurourology and urodynamics·2020

Area of Science:

  • Pharmacology
  • Urology
  • Reproductive Medicine

Background:

  • Erectile dysfunction (ED) and female sexual dysfunction are significant health concerns.
  • Current treatments for sexual dysfunction have limitations.
  • Peptide-based therapeutics offer novel treatment avenues.

Purpose of the Study:

  • To evaluate the efficacy and safety of PT-141 nasal spray for treating erectile dysfunction (ED).
  • To explore the potential of PT-141 in addressing female sexual dysfunction.

Main Methods:

  • PT-141, a synthetic analog of PT-14, was developed as a nasal spray formulation.
  • A Phase IIb clinical trial was conducted in patients diagnosed with ED.
  • Planning for Phase III trials was initiated based on Phase IIb outcomes.

Main Results:

  • Phase IIb trial in ED patients was successfully completed in September 2003.
  • Positive outcomes from Phase IIb supported progression to further clinical development.
  • The study design paved the way for larger-scale Phase III investigations.

Conclusions:

  • PT-141 demonstrates potential as a novel therapeutic agent for sexual dysfunction.
  • Nasal spray delivery of PT-141 offers a promising alternative treatment option.
  • Further clinical trials are warranted to confirm efficacy and safety in broader populations.

Related Experiment Videos